Nanoscope Therapeutics Announces the Appointment of Samuel Barone, MD, as Chief Medical Officer
Barone is a former FDA officer.
Samuel Barone, MD, joins Nanoscope Therapeutics Inc. as chief medical officer.
Nanoscope Therapeutics announced the appointment in a press release. Barone comes to Nanoscope from Gemini Therapeutics, where he served as chief medical officer.
"We are thrilled to welcome Dr. Barone to the Nanoscope team. The regulatory expertise garnered during his tenure at the FDA will be instrumental as we continue to advance our pipeline through late-stage clinical development and navigate the regulatory process," said Sulagna Bhattacharya, co-founder and CEO of Nanoscope. "Dr. Barone will support our mission to bring sight-restoring therapies to patients with inherited retinal diseases in an expeditious manner."
"Nanoscope has the potential to impact the treatment landscape with its gene-agnostic, sight-restoring optogenetic therapies and bring these transformative therapeutic options to patients with severe vision loss due to inherited retinal diseases, for which there are no restorative therapies available," said Dr. Barone. "I look forward to taking MCO-010 through approval and advancing Nanoscope's follow-on assets to the clinic."
Barone is a board-certified ophthalmologist and vitreoretinal surgeon. He also has experience with clinical development.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
